Discordant <i>Clostridioides difficile</i> testing as a predictor of inflammatory bowel disease therapy escalation

20260 citationsJournal Article

Authors

Pavithra Ramakrishnan · University of Minnesota

James Campbell · MNGI Digestive Health

Daphne Moutsoglou · University of Minnesota

Megan B. Ghai · University of Minnesota

Eugenia Shmidt · University of Minnesota

Byron P. Vaughn · University of Minnesota

Abstract

Elevated CRP may help distinguish true CDI in IBD. PCR+/TOX+ patients typically respond to CDI-directed therapy, whereas PCR+/TOX- patients more often require escalation of IBD treatment, suggesting noninfectious inflammation as the primary driver of symptoms.

Topics & Keywords

Clostridium difficile and Clostridium perfringens research Helicobacter pylori-related gastroenterology studies Gastrointestinal motility and disorders

Publication Details

Published in: Inflammatory Bowel Diseases

DOI: 10.1093/ibd/izag038

Field-Weighted Citation Impact: 0.00

Command Palette

Discordant <i>Clostridioides difficile</i> testing as a predictor of inflammatory bowel disease therapy escalation

Authors

Abstract

Topics & Keywords

Publication Details